The Stanford Applied Longevity Translation Symposium brought together top researchers, biotech founders, and investors to discuss how to translate longevity science into real-world impact. Co-organized by LongeVC and our operating partner Artem Trotsyuk, the event explored the latest advancements in regenerative medicine, age-related therapies, and biotech innovation.
The discussions featured key voices in the field, including Vittorio Sebastiano, co-founder of Turn Biotechnologies, a LongeVC portfolio company, alongside Christin Glorioso from NeuroAge Therapeutics and Jean Herbert from ARPA-H. With insights from experts across academia, industry, and venture capital, the symposium reinforced the importance of collaboration in moving longevity research from the lab to practical applications.
Learn more about the event here.
LongeVC remains committed to fostering the conversations and partnerships that will shape the future of healthy aging, ensuring that scientific advancements translate into meaningful change. Reach out to us at hq@longevc.com.
The discussions featured key voices in the field, including Vittorio Sebastiano, co-founder of Turn Biotechnologies, a LongeVC portfolio company, alongside Christin Glorioso from NeuroAge Therapeutics and Jean Herbert from ARPA-H. With insights from experts across academia, industry, and venture capital, the symposium reinforced the importance of collaboration in moving longevity research from the lab to practical applications.
Learn more about the event here.
LongeVC remains committed to fostering the conversations and partnerships that will shape the future of healthy aging, ensuring that scientific advancements translate into meaningful change. Reach out to us at hq@longevc.com.